Canaccord raised the firm’s price target on Neuronetics (STIM) to $8 from $5 and keeps a Buy rating on the shares. The firm said they reported Q4 revenue which was slightly ahead of guidance and management reiterated guidance which was issued in January.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- Neuronetics price target raised to $7 from $3 at Citizens JMP
- 3 Best Stocks to Buy Now, 3/5/2025, According to Top Analysts
- Neuronetics’ Strategic Merger with Greenbrook TMS Fuels Growth and Positive Outlook
- Neuronetics Reports Growth Amid Strategic Acquisitions
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz